Service de Radiologie, Hôpital universitaire Bichat, Paris, France,
Eur Radiol. 2013 Oct;23(10):2830-7. doi: 10.1007/s00330-013-2926-7. Epub 2013 Jun 26.
To assess the potential of intra-tendinous injection of platelet rich plasma (PRP) to treat tendinosis (T+) in a rat model of patellar and Achilles T+, and evaluate its local toxicity.
Thirty rats (120 patellar and Achilles tendons) were used. We induced T+ into 80 tendons (patellar = 40, Achilles = 40) by injecting collagenase at day 0 under ultrasound (US) guidance. Clinical examination and US at day 3, followed by US-guided intra-tendinous injection of either PRP (PRPT+, n = 40) or physiological serum (ST+, n = 40, control). Follow-up was at days 6, 13, 18 and 25 using clinical, US and histological evaluation. To study PRP toxicity, we injected PRP into 40 normal tendons (PRPT-) and compared with 40 untreated normal tendons (T-).
All PRPT+ showed better joint mobilisation compared with ST+ at day 6 (P = 0.005), day 13 (P = 0.02), day 18 (P = 0.003) and day 25 (P = 0.01). Similar results were found regarding US and histology, with smaller collagen fibre diameters (day 6, P = 0.003, day 25, P ≤ 0.004), less disorganisation and fewer neovessels (day 6, P = 0.003, day 25, P = 0.0003) in PRPT+ compared with ST+. Comparison between PRPT- and T- showed no PRP toxicity (P = 0.18).
Our study suggests that mono-injection of PRP in T+ improves tendon healing, with no local toxicity.
• We assessed the potential of platelet rich plasma (PRP) to treat tendinosis. • We treated patellar and Achilles tendinosis in a rat model. • We evaluated clinical, imaging and histological data. • Intra-tendinous PRP injection could be useful in the treatment of tendinosis.
评估在髌腱和跟腱的兔模型中,肌腱内注射富含血小板的血浆(PRP)治疗肌腱病(T+)的潜力,并评估其局部毒性。
本研究共使用 30 只大鼠(120 个髌腱和跟腱)。我们在第 0 天在超声(US)引导下向 80 个肌腱(髌腱=40,跟腱=40)注射胶原酶以诱导 T+。第 3 天进行临床检查和 US,然后对髌腱和跟腱进行 US 引导下的 PRP(PRPT+,n=40)或生理盐水(ST+,n=40,对照组)的肌腱内注射。通过临床、US 和组织学评估,在第 6、13、18 和 25 天进行随访。为了研究 PRP 的毒性,我们将 PRP 注射到 40 个正常肌腱(PRPT-)中,并与 40 个未经处理的正常肌腱(T-)进行比较。
与 ST+相比,所有 PRPT+在第 6 天(P=0.005)、第 13 天(P=0.02)、第 18 天(P=0.003)和第 25 天(P=0.01)时的关节活动度均更好。US 和组织学检查也得到了类似的结果,与 ST+相比,PRPT+中的胶原纤维直径更小(第 6 天,P=0.003,第 25 天,P≤0.004),组织结构紊乱和新生血管更少(第 6 天,P=0.003,第 25 天,P=0.0003)。与 T-相比,PRPT-和 T-之间没有 PRP 毒性(P=0.18)。
本研究表明,T+中单肌腱内注射 PRP 可改善肌腱愈合,无局部毒性。
• 我们评估了富含血小板的血浆(PRP)治疗肌腱病的潜力。
• 我们在兔模型中治疗髌腱和跟腱肌腱病。
• 我们评估了临床、影像学和组织学数据。
• 肌腱内注射 PRP 可能对肌腱病的治疗有用。